Medicenna Therapeutics Statistics
Total Valuation
Medicenna Therapeutics has a market cap or net worth of 73.08 million. The enterprise value is 51.97 million.
| Market Cap | 73.08M |
| Enterprise Value | 51.97M |
Important Dates
The next estimated earnings date is Friday, February 7, 2025.
| Earnings Date | Feb 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.04% |
| Shares Change (QoQ) | +4.37% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 50.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 4.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.63 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.17 |
Financial Position
The company has a current ratio of 11.40, with a Debt / Equity ratio of 0.01.
| Current Ratio | 11.40 |
| Quick Ratio | 11.13 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -122.71% and return on invested capital (ROIC) is -52.52%.
| Return on Equity (ROE) | -122.71% |
| Return on Assets (ROA) | -37.80% |
| Return on Capital (ROIC) | -52.52% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.23M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +174.28% in the last 52 weeks. The beta is 1.19, so Medicenna Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | +174.28% |
| 50-Day Moving Average | 1.15 |
| 200-Day Moving Average | 1.48 |
| Relative Strength Index (RSI) | 36.52 |
| Average Volume (20 Days) | 68,957 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -13.58M |
| Pretax Income | -19.75M |
| Net Income | -19.75M |
| EBITDA | -13.57M |
| EBIT | -13.58M |
| Earnings Per Share (EPS) | -0.27 |
Balance Sheet
The company has 22.52 million in cash and 130,279 in debt, giving a net cash position of 22.39 million.
| Cash & Cash Equivalents | 22.52M |
| Total Debt | 130,279 |
| Net Cash | 22.39M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 14.84M |
| Book Value Per Share | 0.19 |
| Working Capital | 22.07M |
Cash Flow
In the last 12 months, operating cash flow was -12.44 million and capital expenditures -24,427, giving a free cash flow of -12.47 million.
| Operating Cash Flow | -12.44M |
| Capital Expenditures | -24,427 |
| Free Cash Flow | -12.47M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Medicenna Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.04% |
| Shareholder Yield | -4.04% |
| Earnings Yield | -27.03% |
| FCF Yield | -17.06% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |